Exhibit 10.1


 


SECURITIES PURCHASE AGREEMENT


 


This SECURITIES PURCHASE AGREEMENT (this
“Agreement”), dated December 11, 2019, is entered into by and among (i) MARINUS PHARMACEUTICALS, INC., a Delaware
corporation (the “Company”), and (ii) each investor identified on Schedule I (each, including its successors
and permitted assigns, an “Investor” and collectively, the “Investors”).


 


WHEREAS, subject to the terms and conditions
set forth in this Agreement, the Company desires to issue and sell to the Investors an aggregate of 30,000 shares (the “Securities”)
of Series A Participating Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”),
of the Company, which will be convertible into shares (the “Conversion Shares”) of the Company’s common
stock, par value $0.001 per share (“Common Stock”), in accordance with the terms set forth in the Certificate
of Designations establishing the Series A Preferred Stock attached hereto as Exhibit A (the “Certificate of Designations”)
in a private placement pursuant to Section 4(a)(2) of and/or Regulation D under the Securities Act of 1933 (the “Securities
Act”); and


 


WHEREAS, pursuant to the terms and conditions
of the Certificate of Designations, the conversion of the Series A Preferred Stock shall be subject to receipt of the Requisite
Stockholder Approval (as defined therein).


 


NOW THEREFORE, in consideration of the mutual
covenants made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto, intending to be legally bound, agree as follows:


 


1.             Purchase
and Sale of Securities. Subject to the terms and conditions hereof, each Investor agrees, severally and not jointly, to purchase
from the Company, and the Company agrees to sell to the Investors at the Closing, the number of Securities set forth opposite
each such Investor’s name on Schedule I for the price of $1,000.00 per Security and for the aggregate purchase price
set forth on Schedule I (the “Purchase Price”).


 


2.             Issuance
of Securities. Notwithstanding anything in this Agreement to the contrary, the Company shall have no obligation to issue any
of the Securities to any person who is a resident of a jurisdiction in which the issuance of Securities to such person would constitute
a violation of the securities, “blue sky” or other similar laws of such jurisdiction (collectively referred to as
the “State Securities Laws”).


 


3.             The
Closing. The closing of the purchase and sale of the Securities (the “Closing”) shall take place at the
headquarters of the Company, on the third (3rd) Business Day (as defined below) after the date hereof, or at such other time and
place as the Company may designate by notice to the Investors (such date and time being referred to herein as the “Closing
Date”). The term “Business Day” means any day other than a Saturday, a Sunday or a legal holiday
or a day on which banking institutions are authorized or obligated by law to close in New York, New York.


 






     


     


    

 


4.             Payment
for Securities. The Purchase Price shall be received by the Company from the Investors by wire transfer of immediately available
funds to an account designated in writing by the Company or by other means approved by the Company at or prior to the Closing.
At the Closing, following the receipt by the Company of the entire portion of the Purchase Price payable by an Investor, the Company
shall deliver to such Investor copies of (a) a certificate evidencing the number of Securities set forth opposite such Investor’s
name on Schedule I, registered in the name of such Investor and bearing the legend set forth in Section 11 (the
original of such certificate to be delivered to such Investor as promptly as practicable after the Closing Date but in no event
more than three (3) Business Days after the Closing Date) and (b) a certificate from the Secretary of State of the State of Delaware
evidencing the filing of the Certificate of Designations substantially in the form attached hereto as Exhibit A.


 


5.             Representations
and Warranties of the Company. The Company hereby represents and warrants to and covenants with the Investors, as of the date
hereof and as of the Closing, that:


 


(a)           Organization,
Good Standing and Qualification. The Company is duly incorporated and validly existing under the laws of the State of Delaware,
with full corporate power and authority to conduct its business as it is currently being conducted and to own its assets; and
has secured any other authorizations, approvals, permits and orders required by law for the conduct by the Company of its business
as it is currently being conducted.


 


(b)           Authorization.
The Company has all corporate right, power and authority to enter into this Agreement and, subject to receipt of the Requisite
Stockholder Approval, to consummate the transactions contemplated hereby. Subject to receipt of the Requisite Stockholder Approval,
all corporate action on the part of the Company, its directors and stockholders necessary for the authorization, execution, delivery
and performance of this Agreement by the Company and the authorization, sale, issuance and delivery of the Securities contemplated
herein has been taken. This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and
binding obligation of the Company, enforceable against the Company in accordance with its terms, except that such enforceability
(i) may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other similar laws affecting or relating
to creditors’ rights generally and (ii) is subject to general principles of equity.


 


(c)           Capitalization.


 


(i)            As of December 10, 2019, the authorized capital stock of the Company consisted of 25,000,000 shares of preferred
stock, par value $0.001 per share (the “Preferred Stock”), none of which were issued and outstanding, and 100,000,000
shares of Common Stock, 54,271,122 shares of which were issued and outstanding. The Preferred Stock and the Common Stock are collectively
referred to herein as the “Capital Stock.” All of the issued and outstanding shares of Capital Stock have been
duly authorized, validly issued and are fully paid and nonassessable. As of December 10, 2019, 8,831,488 shares of Common Stock
were issuable upon the exercise or vesting of outstanding warrants, options, restricted stock units and other stock-based awards
and 349,753 shares of Common Stock were reserved for future awards under the Company’s 2014 Equity Incentive Plan, as amended.
Except as otherwise set forth in this Agreement, and except as contemplated in the Concurrent Common Stock Offering (as defined
below), as of the date hereof there are no outstanding options, warrants, rights (including conversion or preemptive rights), agreements,
arrangements or commitments of any character, whether or not contingent, relating to the issued or unissued Capital Stock of the
Company or obligating the Company to issue or sell any share of Capital Stock of, or other equity interest in, the Company.


 






    2


     


    

 


(ii)           The issuance of the Securities has been duly authorized and the Securities, when issued and paid for in accordance
with the terms of this Agreement, will be validly issued, fully paid and non-assessable, and shall be free and clear of any encumbrances,
preemptive rights or restrictions (other than as provided in this Agreement or any restrictions on transfer generally imposed under
applicable securities laws). Subject to receipt of the Requisite Stockholder Approval, the Conversion Shares, when issued in accordance
with the terms of the Certificate of Designations, will be validly issued, fully paid and non-assessable, and shall be free and
clear of any encumbrances, preemptive rights or restrictions (other than as provided in this Agreement or any restrictions on transfer
generally imposed under applicable securities laws). Upon receipt of the Requisite Stockholder Approval, the Company shall have
reserved such number of shares of Common Stock sufficient to enable the full conversion of all of the Securities.


 


(d)           Consents.
The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority or other person in connection with
the execution, delivery and performance by the Company of this Agreement, other than the Requisite Stockholder Approval, filings
that have been made, or will be made, pursuant to the rules and regulations of the Nasdaq Global Market (“Nasdaq”),
post-sale filings that may be required pursuant to applicable federal and State Securities Laws which the Company undertakes to
file or obtain within the applicable time periods, and the filing of the Certificate of Designations with the Delaware Secretary
of State.


 


(e)           Securities
Laws. Assuming the accuracy of each Investor’s representations and warranties set forth in Section 6, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Investors as contemplated
hereby.


 


(f)            Litigation.
There is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened in writing
against the Company or any of its directors and officers that questions the validity of this Agreement or the right of the Company
to enter into this Agreement or to consummate the transactions contemplated hereby. There is no action, suit, proceeding or investigation
pending or, to the Company’s knowledge, currently threatened in writing against the Company or any subsidiary or any of
their respective directors and officers which would have, either individually or in the aggregate, a Material Adverse Effect (as
defined below).


 


(g)           Filings.
Since January 1, 2019, the Company has filed all forms, reports and documents required to be filed by it with the Securities and
Exchange Commission (the “Commission”) (collectively, the “Company SEC Reports”). As of
the respective dates they were filed (except if amended, updated or superseded by a filing made by the Company with the Commission
prior to the date of this Agreement, then on the date of such filing), the Company SEC Reports complied in all material respects
with the requirements of the Securities Act or the Securities Exchange Act of 1934 (the “Exchange Act”), as
the case may be, and the applicable rules and regulations of the Commission thereunder. As of their respective dates, the Company
SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.
None of the Company SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading.


 






    3


     


    

 


(h)           Financial
Statements. The consolidated financial statements of the Company (including any notes thereto) contained in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2018 and any Current Reports on Form 8-K filed by the Company subsequent
to December 31, 2018 and through the date of this Agreement with the Commission, including the information incorporated by reference
therein (collectively, the “Disclosure Package”) (i) complied as to form in all material respects with the
published rules and regulations of the Commission with respect thereto, (ii) were prepared in accordance with United States generally
accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods indicated (except
as may be indicated in the notes thereto or, in the case of unaudited financial statements, as permitted by Form 10-Q or Form
8-K) and (iii) each presented fairly, in all material respects, the consolidated financial position of the Company and its consolidated
subsidiaries as of the respective dates thereof and for the respective periods indicated therein, except as otherwise noted therein
(subject, in the case of unaudited financial statements, to normal and recurring year-end adjustments which were not and are not
expected, individually or in the aggregate, to have a Material Adverse Effect). The Company has not had any material disagreement
with its auditors regarding accounting matters or policies during any of its past three (3) full fiscal years or during the current
fiscal year-to-date, which disagreements would require disclosure to the Company’s Board of Directors.


 


(i)            Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company or any subsidiary of the Company
to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person with respect
to the sale of the Securities pursuant to this Agreement, other than Oppenheimer & Co. Inc., Ladenburg Thalmann & Co.
Inc. and certain other investment banks acting as underwriters in connection with the Concurrent Common Stock Offering (as defined
herein) (collectively, the “Placement Agents”). The Investors shall have no obligation with respect to any fees or
with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this Section 5(i) that
may be due in connection with the transactions contemplated by this Agreement.


 


(j)            Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by this Agreement and the Concurrent
Common Stock Offering which will be timely publicly disclosed by the Company, the Company confirms that neither it nor any other
Person acting on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes
material, non-public information which is not otherwise disclosed in the Disclosure Package. The Company understands and confirms
that the Investor will rely on the foregoing representation in effecting purchases and sales of securities of the Company. All
of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its business and the transactions
contemplated hereby, taken as a whole, is true and correct in all material respects and does not contain any untrue statement
of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve (12)
months preceding the Execution Date taken as a whole do not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made and when made, not misleading. The Company acknowledges and agrees that the Investor neither makes
nor has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Section 6 hereof.


 






    4


     


    

 


(k)           Acknowledgment
Regarding the Investor’s Purchase of Securities. The Company acknowledges and agrees that each Investor is acting solely
in the capacity of an arm’s-length purchaser with respect to this Agreement and the transactions contemplated hereby. The
Company further acknowledges that no Investor is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given by any Investor or any
of its representatives or agents in connection with this Agreement and the transactions contemplated hereby is merely incidental
to the Investors’ purchase of the Securities. The Company further represents to the Investors that the Company’s decision
to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the
Company and its representatives.


 


(l)            Acknowledgment
Regarding the Investor’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Section 6(a)(iv) and Section 13), it is understood and acknowledged by the Company that: (i) the Investors
have not been asked by the Company to agree, nor has any Investor agreed, to desist from purchasing or selling, long and/or short,
securities of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities
for any specified term, (ii) past or future open market or other transactions by any Investor, specifically including short sales
or “derivative” transactions, before or after the Closing, may negatively impact the market price of the Company’s
publicly-traded securities, (iii) any Investor, and counter-parties in “derivative” transactions to which any such
Investor is a party, directly or indirectly, may presently have a “short” position in the Common Stock and (iv) no
Investor shall be deemed to have any affiliation with or control over any arm’s-length counter-party in any “derivative”
transaction. The Company further understands and acknowledges that (y) the Investors may engage in hedging activities at various
times during the period that the Securities are outstanding, and (z) such hedging activities (if any) could reduce the value of
the existing stockholders’ equity interests in the Company at and after the time that the hedging activities are being conducted.
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of this Agreement.


 


(m)          No
Disqualification Event. None of the Company, any of its predecessors, any director, executive officer, other officer of the
Company participating in the offering, any beneficial owner (as that term is defined in Rule 13d-3 under the Exchange Act) of
20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale
of any Securities (but, in each case, excluding the Investors, as to whom no representation is made) (each, an “Issuer
Covered Person” and, collectively, “Issuer Covered Persons”) is subject to any of the “Bad
Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company
has exercised reasonable care to determine (i) the identity of each person that is an Issuer Covered Person; and (ii) whether
any Issuer Covered Person is subject to a Disqualification Event. The Issuer has complied, to the extent applicable, with its
disclosure obligations under Rule 506(e) under the Securities Act, and has furnished to the Investors a copy of any disclosures
provided thereunder.


 






    5


     


    

 


6.             Representations
and Warranties of the Investors. As of the date hereof and as of the Closing, each Investor, severally and not jointly, hereby
represents and warrants to and covenants with the Company that:


 


(a)           General.


 


(i)            Such Investor has all requisite authority to purchase the Securities, enter into this Agreement and to perform all
the obligations required to be performed by such Investor hereunder, and such purchase will not contravene any law, rule or regulation
binding on such Investor or any investment guideline or restriction applicable to such Investor.


 


(ii)           Such Investor is acquiring the Securities for its own account and is not acquiring the Securities as a nominee or
agent or otherwise for any other person.


 


(iii)          Such Investor will comply with all applicable laws and regulations such Investor is required to comply with in connection
with the purchase or sale of Securities in effect in any jurisdiction in which such Investor purchases or sells Securities and
obtain any consent, approval or permission such Investor is required to obtain in connection with such purchase or sale of Securities
under the laws and regulations of any jurisdiction to which such Investor is subject or in which such Investor makes such purchases
or sales, and the Company shall have no responsibility therefor.


 


(iv)          Other than consummating the transactions contemplated hereby, such Investor has not directly or indirectly, nor has
any person acting on behalf of or pursuant to any understanding with such Investor, executed any purchases or sales, including
short sales, of the securities of the Company during the period commencing as of the time that such Investor first received a term
sheet (written or oral) from the Company or any other person representing the Company setting forth the material terms of the transactions
contemplated hereby and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of an Investor
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor’s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Investor’s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.
Other than to other persons party to this Agreement, such Investor has maintained the confidentiality of all disclosures made to
it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to the identification of the availability of, or securing of, available shares to borrow in order to effect short sales or similar
transactions in the future.


 






    6


     


    

 


(b)           Information
Concerning the Company.


 


(i)            Such Investor understands and accepts that the purchase of the Securities involves various risks. Such Investor represents
that it is able to bear a complete loss of its investment in the Securities.


 


(ii)           Such Investor confirms that it is not relying on any communication (written or oral) of the Company or any of its
affiliates, as investment advice or as a recommendation to purchase the Securities. It is understood that information and explanations
related to the terms and conditions of the Securities provided by the Company or any of its affiliates shall not be considered
investment advice or a recommendation to purchase the Securities, and that neither the Company nor any of its affiliates is acting
or has acted as an advisor to such Investor in deciding to invest in the Securities. Such Investor acknowledges that neither the
Company nor any of its affiliates has made any representation regarding the proper characterization of the Securities for purposes
of determining such Investor’s authority to invest in the Securities.


 


(iii)          Such Investor acknowledges that it has had the opportunity to review this Agreement (including all exhibits and schedules
hereto) and the Disclosure Package and has been afforded (A) the opportunity to ask such questions as it has deemed necessary of,
and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (B) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (C)
the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or
expense that is necessary to make an informed investment decision with respect to the investment.


 


(iv)          Such Investor understands that, unless such Investor notifies the Company in writing to the contrary at or before
the Closing, each of such Investor’s representations and warranties contained in this Agreement will be deemed to have been
reaffirmed and confirmed as of the Closing, taking into account all information received by such Investor.


 


(v)           Such Investor understands that no federal or state agency has passed upon the merits or risks of an investment in
the Securities or made any finding or determination concerning the fairness or advisability of this investment.


 


(vi)          Such Investor is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented
at any seminar or any other general solicitation or general advertisement.


 






    7


     


    

 


(c)           Non-reliance.


 


(i)            Such Investor represents that it is not relying on (and will not at any time rely on) any communication (written
or oral) of the Company, as investment advice or as a recommendation to purchase the Securities, it being understood that information
and explanations related to the terms and conditions of the Securities shall not be considered investment advice or a recommendation
to purchase the Securities.


 


(ii)           Except as expressly provided herein, such Investor confirms that the Company has not (A) given any guarantee or representation
as to the potential success, return, effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) an of
investment in the Securities or (B) made any representation to such Investor regarding the legality of an investment in the Securities
under applicable legal investment or similar laws or regulations. In deciding to purchase the Securities, such Investor is not
relying on the advice or recommendations of the Company and such Investor has made its own independent decision that the investment
in the Securities is suitable and appropriate for such Investor.


 


(d)           Status
of the Investor.


 


(i)            Such Investor has such knowledge, sophistication, skill and experience in business, financial and investment matters
that such Investor is capable of evaluating the merits and risks of an investment in the Securities, and has so evaluated the merits
and risks of such investment. With the assistance of such Investor’s own professional advisors, to the extent that such Investor
has deemed appropriate, such Investor has made its own legal, tax, accounting and financial evaluation of the merits and risks
of an investment in the Securities and the consequences of this Agreement. Such Investor has considered the suitability of the
Securities as an investment in light of its own circumstances and financial condition and such Investor is able to bear the risks
associated with an investment in the Securities and its authority to invest in the Securities.


 


(ii)           At the time such Investor was offered the Securities, such Investor was, and as of the date hereof such Investor
is, and on the Closing Date, such Investor will be, an “accredited investor” as defined in Rule 501(a) under the Securities
Act, and not required to be registered as a broker-dealer under Section 15 of the Exchange Act. Such Investor agrees to furnish
any additional information reasonably requested by the Company or any of its affiliates to assure compliance with applicable U.S.
federal and State Securities Laws in connection with the purchase and sale of the Securities.


 


(e)           Restrictions
on Transfer or Sale of Securities.


 


(i)            Such Investor is acquiring the Securities solely for such Investor’s own beneficial account, for investment
purposes, and not with a view to, or for resale in connection with, any distribution of the Securities, has no present intention
of distributing any of such Securities in violation of the Securities Act or any applicable State Securities Laws and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities
in violation of the Securities Act or any applicable State Securities Laws (this representation and warranty not limiting such
Investor’s right to sell the Conversion Shares pursuant to the Registration Statement (as defined below) or otherwise in
compliance with applicable federal law and State Securities Laws). Such Investor understands that the Securities have not been
registered under the Securities Act or any State Securities Laws by reason of specific exemptions under the provisions thereof
which depend in part upon the investment intent of such Investor and of the other representations made by such Investor in this
Agreement. Such Investor understands that the Company is relying upon the representations and agreements contained in this Agreement
for the purpose of determining whether this transaction meets the requirements for such exemptions.


 






    8


     


    

 


(ii)           Such Investor understands that the Securities are “restricted securities” under applicable federal securities
laws and that the Securities Act and the rules of the Commission provide in substance that such Investor may dispose of the Securities
only pursuant to an effective registration statement under the Securities Act or an exemption therefrom such as the exemption and
safe harbor provided under Rule 144 of the Securities Act.


 


(iii)          Such Investor agrees that such Investor will not sell, assign, pledge, give, transfer or otherwise dispose of the
Securities or any interest therein, or make any offer or attempt to do any of the foregoing, except pursuant to a registration
of the Securities under the Securities Act or in a transaction which is exempt from the registration provisions of the Securities
Act such as the exemption and safe harbor provided under Rule 144 of the Securities Act; that the certificates representing the
Securities will bear a legend making reference to the foregoing restrictions; and that the Company and its affiliates and transfer
agent shall not be required to give effect to any purported transfer of such Securities except upon compliance with the foregoing
restrictions. The Company acknowledges and agrees that such Investor may from time to time pledge pursuant to a bona fide margin
agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution
that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the
provisions of this Agreement and, if required under the terms of such arrangement, such Investor may transfer pledged or secured
Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no
legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no
notice shall be required of such pledge.


 


(iv)          No Disqualification Events. Each Investor represents that neither it, nor any of its directors, officers,
general partners or managing members, is subject to any Disqualification Event except for a Disqualification Event (i) contemplated
by Rule 506(d)(2) under the Securities Act and (ii) a description of which has been furnished in writing to the Issuer prior to
the date hereof.


 


(f)            Bad
Actor Disclosure. Such Investor hereby acknowledges and agrees that it has received and reviewed the disclosure set forth on
Annex I attached hereto a reasonable time prior to the time that such Investor has agreed to purchase the Securities.


 


7.             Conditions
to Obligations of the Investors and the Company. The obligations of the Investors to purchase and pay for the Securities are
subject to the condition that the representations and warranties of the Company contained in Section 5 shall be true and
correct as of the Closing in all respects with the same effect as though such representations and warranties had been made as
of the Closing, and the obligation of the Company to sell the Securities is subject to the condition that the representations
and warranties of the Investors contained in Section 6 shall be true and correct as of the Closing in all respects with
the same effect as though such representations and warranties had been made as of the Closing. The obligations of the Investors
to purchase and pay for the Securities and of the Company to sell the Securities are subject to the satisfaction at or prior to
the Closing of the following further conditions precedent:


 






    9


     


    

 


(a)           No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered or promulgated
by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated
by this Agreement.


 


(b)           There shall not have been a Material Adverse Effect. For purposes of this Agreement, a “Material Adverse
Effect” means any event, change, violation, inaccuracy, circumstance or effect that, individually or in the aggregate,
has had or would reasonably be expected to have a material adverse effect on, or result in a material adverse change in, as the
case may be, the business, operations, properties, condition (financial or otherwise), assets, liabilities or results of operations
of the Company, except for any such events, changes, violations, inaccuracies, circumstances or effects resulting from (i) any
changes in general economic, regulatory or political conditions, (ii) any changes or events generally affecting the industry in
which the Company operates, (iii) any adverse change or effect that is caused by the announcement of the transactions contemplated
by this Agreement, or (iv) any violations or other matters arising from changes in law or GAAP; unless in any such instance such
change or effect described in (i), (ii) or (iv) impacts the Company in a materially disproportionate manner relative to a preponderance
of the other similar entities impacted by such change.


 


(c)           The Company shall have completed the concurrent public offering of Common Stock being made pursuant to the Company’s
registration statement on Form S-3 (File No. 333- 221243) (the “Concurrent Common Stock Offering”).


 


8.             Certain
Covenants of the Company.


 


(a)           The Company hereby agrees to use reasonable best efforts (i) to maintain the listing or quotation of the Common Stock
on Nasdaq (or such other trading market that the Company applies to have the Common Stock traded on) for so long as any Investor
owns unregistered Securities, and (ii) as promptly as practicable following the receipt of the Requisite Stockholder Approval,
to secure the listing of the Conversion Shares (subject to official notice of issuance) on such trading market.


 


(b)           The Company shall file a Current Report on Form 8-K and press release disclosing the material terms of the transactions
contemplated hereby. Such press release will be issued prior to market open on the Business Day following the date of this Agreement
and the Form 8-K will be filed within the time prescribed by the regulations of the Commission.


 






    10


     


    

 


(c)           For so long as any Investor holds unregistered Securities, (i) the Company shall use its reasonable best efforts
to timely file (or file within the applicable grace period after having obtained, if necessary, extensions in respect thereof)
all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act and (ii) if the Company is not
required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Investors and make publicly available
in accordance with Rule 144(c) such information as is required for the Investors to sell the Conversion Shares under Rule 144.


 


(d)           No claim will be made or enforced by the Company or, with the consent of the Company, any other person, that any
Investor is an “Acquiring Person” or a “20% Stockholder” under any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in
effect or hereafter adopted by the Company or that any Investor could be deemed to trigger the provisions of any such plan or arrangement
by virtue of receiving Securities pursuant to this Agreement.


 


(e)           The Company shall continue to reserve and keep available at all times from the date of receipt of the Requisite Stockholder
Approval through the date on which the Securities have been converted in full, free of preemptive rights, a sufficient number of
shares of Common Stock for the purpose of enabling the Company to issue the Conversion Shares pursuant to any conversion of any
Securities in accordance with the Certificate of Designations.


 


9.             Registration
Rights.


 


(a)           Shelf
Registration.


 


(i)            The Company shall use commercially reasonable efforts to file no later than 30 days after receipt of the Requisite
Stockholder Approval (the “Filing Date”) a registration statement covering the resale of the Conversion Shares
(the “Registrable Shares”) with the Commission for an offering to be made on a continuous basis pursuant to
Rule 415, or if Rule 415 is not available for offers and sales of the Registrable Shares, by such other means of distribution of
Registrable Shares as the Investors may reasonably specify (the “Initial Registration Statement”).


 


(ii)           The Company shall use commercially reasonable efforts to effect the registration (including a declaration of effectiveness
thereof by the Commission) and applicable qualifications or compliances (including the execution of any required undertaking to
file post-effective amendments, appropriate qualifications or exemptions under applicable State Securities Laws and appropriate
compliance with applicable securities laws, requirements or regulations) as promptly as practicable after the filing of the Initial
Registration Statement, but in any event prior to the date which is 120 days after the Filing Date (the “Effectiveness
Date”). The Company shall, within two (2) Business Days after the Effectiveness Date, file a final prospectus with the
Commission as required by Rule 424 under the Securities Act.


 


(iii)          In the event that all of the Registrable Shares cannot, as a result of the rules and regulations of the Commission,
be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform
the Investors, (ii) use commercially reasonable efforts to file amendments to the Initial Registration Statement as required by
the Commission and/or (iii) withdraw the Initial Registration Statement and use commercially reasonable efforts to file a new registration
statement (a “New Registration Statement”), in either case covering the maximum number of Registrable Shares
permitted to be registered by the Commission, on Form S-3 or, if the Company is ineligible to register for resale the Registrable
Shares on Form S-3, such other form available to register for resale the Registrable Shares as a secondary offering; provided,
however, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use commercially
reasonable efforts to advocate with the Commission for the registration of all of the Registrable Shares. In the event the Company
amends the Initial Registration Statement or files a New Registration Statement, as the case may be, under clauses (ii) or (iii)
above, the Company will use commercially reasonable efforts to file with the Commission, as promptly as practicable, one or more
registration statements on Form S-3 or, if the Company is ineligible to register for resale the Registrable Shares on Form S-3,
such other form available to register for resale those Registrable Shares that were not registered for resale on the Initial Registration
Statement, as amended, or the New Registration Statement (the “Remainder Registration Statements” and, collectively
with the Initial Registration Statement and the New Registration Statement, the “Registration Statements”).


 






    11


     


    

 


(iv)          Notwithstanding any other provision of this Agreement, if the Commission limits the number of Registrable Shares
permitted to be registered on a particular Registration Statement (and notwithstanding that the Company used diligent efforts to
advocate with the Commission for the registration of all or a greater number of Registrable Shares), unless otherwise directed
in writing by any Investor as to its Registrable Shares, the number of Registrable Shares to be registered on such Registration
Statement will be reduced as follows:


 


(1)           First, the Company shall reduce or eliminate any securities to be included other than Registrable Shares;


 


(2)           Second, the Company shall reduce Registrable Shares (applied to the Investors on a pro rata basis based on the total
number of unregistered Registrable Shares held by such Investors).


 


In the event of a cutback hereunder, the
Company shall give the Investors at least three (3) Business Days prior written notice along with the calculations as to such Investor’s
allotment.


 


(b)           Fees
and Expenses. All expenses incurred by the Company in complying with Section 9(a), including all registration, qualification
and filing fees, printing expenses, fees and expenses of counsel for the Company, blue sky fees and expenses and the expense of
any special audits incident to or required by any such registration (but excluding the fees of legal counsel for any Investor
or any holder of Registrable Shares) shall be borne by the Company. All selling commissions applicable to the sale of Registrable
Shares and all fees and expenses of legal counsel for any Investor or any holder of Registrable Shares related to the registration
and sale of the Registrable Shares shall be borne by the Investor or holder of Registrable Shares incurring such commissions,
fees or expenses; provided, however, that the Company shall pay the fees and expenses of one counsel for all Investors selling
shares in such registration.


 






    12


     


    

 


(c)           Certain
Actions and Notifications. In the case of the registration, qualification, exemption or compliance effected by the Company
pursuant to this Agreement, the Company shall, upon reasonable request, inform the Investors as to the status of such registration,
qualification, exemption and compliance. At its expense the Company shall:


 


(i)            except for such times as the Company is permitted hereunder to suspend the use of the prospectus forming part of
a Registration Statement, use its commercially reasonable efforts to keep such registration, and any qualification, exemption or
compliance under State Securities Laws which the Company determines to obtain, continuously effective with respect to the Investors,
and to keep the applicable Registration Statement effective until the earlier of (A) two (2) years from the Closing Date, (B) the
date by which all the Registrable Shares may be sold without volume or manner of sale restrictions which may be applicable to affiliates
under Rule 144, or (C) the date on which all of the Registrable Shares are sold. The period of time during which the Company is
required hereunder to keep a Registration Statement effective is referred to herein as the “Registration Period”;


 


(ii)           advise the Investors within five (5) Business Days:


 


(1)           when a Registration Statement or any amendment thereto has been filed with the Commission and when such Registration
Statement or any post-effective amendment thereto has become effective;


 


(2)           of any request by the Commission for amendments or supplements to any Registration Statement or the prospectus included
therein or for additional information;


 


(3)           of the issuance by the Commission of any stop order suspending the effectiveness of any Registration Statement or,
to the Company’s knowledge, the initiation of any proceedings for such purpose;


 


(4)           of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable
Shares included therein for sale in any jurisdiction or, to the Company’s knowledge, the initiation or threatening of any
proceeding for such purpose; and


 


(5)           subject to the provisions of this Agreement, of the occurrence of any event that requires the making of any changes
in any Registration Statement or prospectus so that, as of such date, the statements therein do not include any untrue statement
of a material fact and do not omit to state a material fact required to be stated therein or necessary to make the statements therein
(in the case of a prospectus, in the light of the circumstances under which they were made) not misleading;


 


(iii)          use its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any
Registration Statement as soon as reasonably practicable;


 


(iv)          if any Investor so requests in writing, promptly furnish to such Investor, without charge, at least one copy of each
Registration Statement and each post-effective amendment thereto, including financial statements and schedules, and, if explicitly
requested, all exhibits in the form filed with the Commission;


 






    13


     


    

 


(v)           during the Registration Period, promptly deliver to the Investors, without charge, as many copies of each prospectus
included in a Registration Statement and any amendment or supplement thereto as any Investor may reasonably request in writing;
and the Company consents to the use, consistent with the provisions hereof, of the prospectus or any amendment or supplement thereto
by such Investor of Registrable Shares in connection with the offering and sale of the Registrable Shares covered by a prospectus
or any amendment or supplement thereto;


 


(vi)          during the Registration Period, if any Investor so requests in writing, deliver to such Investor, without charge,
(i) one copy of the following documents, other than those documents available via the Commission’s EDGAR system: (A) its
annual report on Form 10-K (or similar form), (B) its definitive proxy statement with respect to its annual meeting of stockholders,
(C) each of its quarterly reports on Form 10-Q, and (D) a copy of each full Registration Statement (the foregoing, in each case,
excluding exhibits); and (ii) if explicitly requested, all exhibits excluded by the parenthetical to the immediately preceding
clause (D); provided, that the Company shall have no obligation to provide any document pursuant to this clause that is
available on the Commission’s EDGAR system;


 


(vii)         prior to any public offering of Registrable Shares pursuant to any Registration Statement, promptly take such actions
as may be necessary to register or qualify or obtain an exemption for offer and sale under State Securities Laws of such United
States jurisdictions as any Investor reasonably request in writing; provided that the Company shall not for any such purpose
be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified
or to consent to general service of process in any such jurisdiction, and do any and all other acts or things reasonably necessary
or advisable to enable the offer and sale in such jurisdictions of the Registrable Shares covered by any such Registration Statement;


 


(viii)        upon the occurrence of any event contemplated by Section 9(c)(ii)(5), except for such times as the Company
is permitted hereunder to suspend the use of a prospectus forming part of a Registration Statement, and taking into account the
Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure
of such event, the Company shall use its commercially reasonable efforts to prepare a post-effective amendment to such Registration
Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers
of the Registrable Shares included therein, such prospectus will not include any untrue statement of a material fact or omit to
state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading;


 


(ix)           otherwise use its commercially reasonable efforts to comply in all material respects with all applicable rules and
regulations of the Commission which could affect the sale of the Registrable Shares;


 






    14


     


    

 


(x)            use its commercially reasonable efforts to cause all Registrable Shares to be listed on each securities exchange
or market, if any, on which equity securities issued by the Company have been listed; and


 


(xi)           cooperate with any broker-dealer through which any Investor proposes to resell its Registrable Shares in such broker-dealer’s
filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110, as requested by such Investor.


 


(d)           No
Delays. The Investors shall not have the right to take any action to restrain, enjoin or otherwise delay any registration
pursuant to Section 9(a) as a result of any controversy that may arise with respect to the interpretation or implementation
of this Agreement.


 


(e)           Special
Interest. If the Company has not (i) filed the Initial Registration Statement by the Filing Date or (ii) effected the registration
of the Registrable Shares by the Effectiveness Date (each such event referred to in clauses (i) and (ii), a “Registration
Default”) or (iii) after the effective date of a Registration Statement, such Registration Statement ceases for any
reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders
are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than 20 consecutive
calendar days or more than an aggregate of 35 calendar days (which need not be consecutive calendar days) during any 12-month
period (any such failure or breach under clause (iii) being referred to as a “Lapse Event” and, for purpose
of clause (iii) the date on which such 20 or 35 calendar day period, as applicable, is exceeded being referred to as “Event
Date”), then the Company shall pay to the Investors interest (“Special Interest”), not as a penalty,
in an amount, with respect to clauses (i) and (ii) per annum equal to 0.15% of such Investor’s Purchase Price for each day
that the Registration Default continues and, with respect to clause (iii), on each such Event Date and on each monthly anniversary
of each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured,
the Company shall pay to each Investor an amount in cash, as liquidated damages and not as a penalty, equal to 0.15% of such Investor’s
Purchase Price; provided, however, that the Company shall in no event be required to pay Special Interest for more than
one Registration Default at any given time and in no event shall the maximum aggregate liquidated damages payable to an Investor
under this Section 9(e) exceed 4% of such Investor’s Purchase Price. A Registration Default ends upon termination of the
Registration Period or, if earlier, (x) in the case of a Registration Default under clause (i) of the definition thereof, when
the Initial Registration Statement is filed with the Commission or (y) in the case of a Registration Default under clause (ii)
of the definition thereof, when the Initial Registration Statement becomes or is declared effective by the Commission. All accrued
Special Interest shall be paid by the Company to each Investor on a quarterly basis to an account designated in writing by such
Investor. Notwithstanding anything contained herein to the contrary, the payment of Special Interest shall be the only remedy
available to the Investor for any Registration Default.


 






    15


     


    

 


(f)            Indemnification.


 


(i)            To the extent permitted by law, the Company shall indemnify each Investor and each person controlling such Investor
within the meaning of Section 15 of the Securities Act, with respect to which any registration that has been effected pursuant
to this Agreement, against all claims, losses, damages and liabilities (or action in respect thereof), including any of the foregoing
incurred in settlement of any litigation, commenced or threatened (subject to Section 9(f)(iii)), arising out of or based
on any untrue statement (or alleged untrue statement) of a material fact contained in any Registration Statement, prospectus, any
amendment or supplement thereof, or other document incident to any registration, qualification or compliance or based on any omission
(or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein
not misleading, in light of the circumstances in which they were made, or any violation by the Company of any rule or regulation
promulgated by the Securities Act applicable to the Company and relating to any action or inaction required of the Company in connection
with any such registration, qualification or compliance, and will reimburse such Investor and each person controlling such Investor,
for reasonable legal and other out-of-pocket expenses reasonably incurred in connection with investigating or defending any such
claim, loss, damage, liability or action as incurred; provided that the Company will not be liable in any such case to the
extent that any untrue statement or omission or allegation thereof is made in reliance upon and in conformity with written information
furnished to the Company by or on behalf of such Investor for use in preparation of any Registration Statement, prospectus, amendment
or supplement; provided however, that the Company will not be liable in any such case where the claim, loss, damage or liability
arises out of the failure of such Investor to comply with the covenants and agreements contained in this Agreement respecting sales
of Registrable Shares, and except that the foregoing indemnity agreement is subject to the condition that, insofar as it relates
to any such untrue statement or alleged untrue statement or omission or alleged omission made in any preliminary prospectus but
eliminated or remedied in the amended prospectus on file with the Commission at the time any Registration Statement becomes effective
or in an amended prospectus filed with the Commission pursuant to Rule 424(b) which meets the requirements of Section 10(a) of
the Securities Act (each, a “Final Prospectus”), such indemnity shall not inure to the benefit of such Investor
or any such controlling person, if a copy of a Final Prospectus furnished by the Company to such Investor for delivery was not
furnished to the person or entity asserting the loss, liability, claim or damage at or prior to the time such furnishing is required
by the Securities Act and a Final Prospectus would have cured the defect giving rise to such loss, liability, claim or damage.


 


(ii)           Each Investor shall, severally and not jointly, indemnify the Company, each of its directors and officers, and each
person who controls the Company within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and
liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced
or threatened (subject to Section 9(f)(iii)), arising out of or based on any untrue statement (or alleged untrue statement)
of a material fact contained in any Registration Statement, prospectus, any amendment or supplement thereof, or other document
incident to any such registration, or based on any omission (or alleged omission) to state therein a material fact required to
be stated therein or necessary to make the statements therein not misleading, in light of the circumstances in which they were
made, and will reimburse the Company, such directors and officers, and each person controlling the Company for reasonable legal
and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability
or action as incurred, in each case to the extent, but only to the extent, that such untrue statement or omission or allegation
thereof is made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Investor
expressly for use in the Registration Statement or any prospectus, amendment or supplement filed thereunder for the Registrable
Shares of such Investor. Notwithstanding the foregoing, the maximum liability of such Investor under this section shall be limited
to the net proceeds received by such Investor from the sale of Registrable Shares.


 






    16


     


    

 


(iii)          Each party entitled to indemnification under this Section 9(f) (the “Indemnified Party”)
shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after
such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying
Party (at its expense) to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel
for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party
(whose approval shall not unreasonably be withheld, conditioned or delayed), and the Indemnified Party may participate in such
defense at such Indemnified Party’s expense, and provided further that the failure of any Indemnified Party to give notice
as provided herein shall not relieve the Indemnifying Party of its obligations under this Agreement, unless such failure is materially
prejudicial to the Indemnifying Party in defending such claim or litigation. An Indemnifying Party shall not be liable for any
settlement of an action or claim effected without its written consent (which consent shall not be unreasonably withheld, conditioned
or delayed). No Indemnifying Party, in its defense of any such claim or litigation, shall, except with the consent of each Indemnified
Party (which consent shall note be unreasonably withheld, conditioned or delayed), consent to entry of any judgment or enter into
any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
Party of a release from all liability in respect to such claim or litigation.


 


(iv)          If the indemnification provided for in this Section 9(f) is held by a court of competent jurisdiction to be
unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or expense referred to therein, then the
Indemnifying Party, in lieu of indemnifying such Indemnified Party thereunder, shall contribute to the amount paid or payable by
such Indemnified Party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect
the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements
or omissions which resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations.
The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information
supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable
if contribution pursuant to this Section 9(f) were determined by pro rata allocation or by any other method of allocation
that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding
the provisions of this Section 9(f), no Investor shall be required to contribute pursuant to this Section 9(f), in
the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Investor from the sale of
the Registrable Shares exceeds the amount of any damages that such Investor has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission.


 






    17


     


    

 


(g)           Disclosure,
Etc.


 


(i)            Not less than five (5) Business Days prior to the filing of each Registration Statement, the Company shall furnish
to each Investor copies of such Registration Statement and all exhibits being filed therewith, and shall consider in good faith
the reasonable comments of such Investor. For purposes of clarification, the Company shall not be obligated to provide the Investors
advance copies of any universal shelf registration statement registering securities in addition to those required hereunder.


 


(ii)           Each Investor agrees that, upon receipt of any notice from the Company of the happening of any event requiring the
preparation of a supplement or amendment to a prospectus relating to Registrable Shares so that, as thereafter delivered to the
Investor, such prospectus shall not contain an untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein not misleading, such Investor will forthwith discontinue disposition
of Registrable Shares pursuant to a Registration Statement and prospectus contemplated by Section 9(a) until its receipt
of copies of the supplemented or amended prospectus from the Company and, if so directed by the Company, such Investor shall deliver
to the Company all copies, other than permanent file copies then in such Investor’s possession, of the prospectus covering
such Registrable Shares current at the time of receipt of such notice.


 


(iii)          Each Investor shall suspend, upon request of the Company, any disposition of Registrable Shares pursuant to any Registration
Statement and prospectus contemplated by Section 9(a) during the occurrence or existence of any pending corporate development
with respect to the Company that the Board of Directors of the Company believes in good faith may be material and that, in the
determination of the Board of Directors of the Company, makes it not in the best interest of the Company to allow continued availability
of a Registration Statement or prospectus. The Company shall be entitled to exercise its right under this paragraph to suspend
the availability of a Registration Statement and prospectus for a period not to exceed 60 calendar days (which need not be consecutive
days) in any 12-month period.


 


(iv)          Upon the occurrence of any event contemplated by Section 9(g)(iii), as promptly as reasonably possible under
the circumstances taking into account the Company’s good faith assessment of any adverse consequences to the Company and
its stockholders of the premature disclosure of such event, the Company shall prepare a supplement or amendment, including a post-effective
amendment, to a Registration Statement or a supplement to the related prospectus or any document incorporated or deemed to be incorporated
therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor
such prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company
will use its best efforts to ensure that the use of the prospectus may be resumed as promptly as is practicable. The Company shall
be entitled to exercise its right under this Section 9(g) to suspend the availability of a Registration Statement and prospectus
for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.


 






    18


     


    

 


(v)           As a condition to the inclusion of its Registrable Shares, each Investor shall furnish to the Company such information
regarding such Investor and the distribution proposed by such Investor as the Company may reasonably request in writing, including
completing a Registration Statement Questionnaire in the form provided by the Company, or as shall be required in connection with
any registration referred to in this Section 9.


 


(vi)          Each Investor hereby covenants with the Company not to make any sale of the Registrable Shares without effectively
causing the prospectus delivery requirements under the Securities Act to be satisfied (unless such sale is pursuant to Rule 144).


 


(vii)         Each Investor agrees not to take any action with respect to any distribution deemed to be made pursuant to a Registration
Statement which would constitute a violation of Regulation M under the Exchange Act or any other applicable rule, regulation or
law.


 


(viii)        At the end of the Registration Period, each Investor shall discontinue sales of shares pursuant to any Registration
Statement upon receipt of notice from the Company of its intention to remove from registration the shares covered by any such Registration
Statement which remain unsold, and the Investors shall notify the Company of the number of shares registered which remain unsold
immediately upon receipt of such notice from the Company.


 


(h)           Assignment.
The rights to cause the Company to register Registrable Shares granted to the Investors by the Company under Section 9(a)
may be assigned by any Investor in connection with a transfer by such Investor of all or a portion of its Registrable Shares,
provided, however, that such Investor must give the Company at least 10 days prior notice of such transfer for such transfer
to be reflected in the Registration Statement or any amendment thereto and that (i) such transfer may otherwise be effected in
accordance with applicable securities laws; (ii) such Investor gives prior written notice to the Company at least 10 days prior
to the transfer; and (iii) such transferee agrees to comply with the terms and provisions of this Agreement, and such transfer
is otherwise in compliance with this Agreement. Except as specifically permitted by this Section 9(h), the rights of an
Investor with respect to Registrable Shares as set out herein shall not be transferable to any other person, and any attempted
transfer by any Investor shall cause all rights of such Investor therein to be forfeited.


 


(i)            Waivers.
The rights of any Investor under any provision of this Section 9 may be waived (either generally or in a particular instance,
either retroactively or prospectively and either for a specified period of time or indefinitely) or amended by an instrument in
writing signed by such Investor.


 


10.           Investors’
Covenant to Convert. Promptly (and in any event within 10 Business Days) following (a) the effectiveness of a registration
statement covering the resale of the Conversion Shares under the Securities Act, and (b) June 30 of each year, each Investor shall
submit a Notice of Conversion (as defined in the Certificate of Designations) to the Company in accordance with Section 6 of the
Certificate of Designations to effect a conversion of the Series A Preferred Stock such that following such conversion such Investor
will either (x) have converted all of the remaining shares of Series A Preferred Stock owned by such Investor, or (y) own a number
of shares of Common Stock equal to the Beneficial Ownership Limit (as defined in the Certificate of Designations) applicable to
such Investor.


 






    19


     


    

 


11.           Legend.
The Securities will be imprinted with a legend in substantially the following form:


 


THIS SECURITY HAS NOT BEEN REGISTERED WITH
THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE
TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT
OR OTHER LOAN SECURED BY SUCH SECURITIES.


 


provided, that the Company shall (a)
cause such legend to be promptly removed once a registration statement covering the resale of any Securities is effective under
the Securities Act or if such legend is no longer required under applicable law and (b) in connection with any sale made under
the Registration Statement or Rule 144, promptly (and in any event within five (5) Business Days after receipt by the Company of
a request therefor accompanied by all reasonably required documentation) deliver, or cause to be delivered, to any Investor new
certificate(s) representing the Conversion Shares that are free from all restrictive and other legends or, at the request of such
Investor, via DWAC transfer to such Investor’s account.


 


12.           Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances
shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement
Securities.


 


13.           Certain
Transactions. Each Investor, severally and not jointly, covenants that neither it, nor any affiliate acting on its behalf
or pursuant to any understanding with it, will execute any purchases or sales, including short sales, of any of the Company’s
securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section 8(b).


 






    20


     


    

 


14.           Expenses.
The parties hereto shall pay their own costs and expenses in connection with the transactions contemplated hereby, provided that
the Company shall pay the reasonable fees and expenses of one counsel for all Investors in connection with the negotiation of
and entry into this Agreement.


 


15.           Waiver,
Amendment. Neither this Agreement nor any provisions hereof shall be amended, waived, discharged or terminated except by an
instrument in writing signed, in the case of an amendment, by the Company and each Investor affected by such amendment or, in
the case of a waiver, discharge or termination, by the party against whom such waiver, discharge or termination is sought.


 


16.           Assignability.
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company
may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investors. Subject
to Section 9(h), any Investor may assign any or all of its rights under this Agreement to any person to whom such Investor
assigns or transfers any Securities; provided that such transferee agrees in writing to be bound, with respect to the transferred
Securities, by the provisions of this Agreement that apply to the “Investors”.


 


17.           Waiver
of Jury Trial. THE COMPANY AND EACH INVESTOR IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL
PROCEEDING ARISING OUT OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.


 


18.           Submission
to Jurisdiction. With respect to any suit, action or proceeding relating to any offers, purchases or sales of the Securities
by the Investors (“Proceedings”), the Company and each Investor irrevocably submits to the jurisdiction of
the federal or state courts located in the State of Delaware, which submission shall be exclusive unless none of such courts has
lawful jurisdiction over such Proceedings.


 


19.           Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware.


 


20.           Section
and Other Headings. The section and other headings contained in this Agreement are for reference purposes only and shall not
affect the meaning or interpretation of this Agreement.


 


21.           Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to
be an original and all of which together shall be deemed to be one and the same agreement.


 


22.           Notices.
All notices and other communications provided for herein shall be in writing and shall be deemed to have been duly given if delivered
personally or sent by registered or certified mail, return receipt requested, postage prepaid, or by facsimile or electronic transmission
to the following addresses (or such other address as either party shall have specified by notice in writing to the other):


 






    21


     


    

 


	If to the Company:	Marinus Pharmaceuticals, Inc.
	 	5 Radnor Corporate Center
	 	100 Matsonford Rd, Suite 100
	 	Radnor, PA 19087
	 	E-mail: esmith@marinuspharma.com
	 	Attention: Edward F. Smith, Chief Financial Officer
	 	 
	 	With a copy (which shall not constitute notice)
    to:
	 	 
	 	Duane Morris LLP
	 	30 S. 17th Street
	 	Philadelphia, PA 19103
	 	E-mail: kmshay@duanemorris.com
	 	Attention: Kathleen M. Shay, Esq.






 


	If to any Investor:	To its address as set forth on Schedule I attached hereto


 


23.           Binding
Effect; Third Party Beneficiaries. The provisions of this Agreement shall be binding upon and accrue to the benefit of the
parties hereto and their respective heirs, legal representatives, successors and assigns. This Agreement is intended for the benefit
of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision
hereof be enforced by, any other person, except that the Placement Agents are third party beneficiaries of the representations
and warranties of each of the Investors and the Company set forth herein.


 


24.           Survival.
All representations, warranties and covenants contained in this Agreement shall survive the Closing.


 


25.           Notification
of Changes. The Company and each Investor hereby covenants and agrees to notify the other upon the occurrence of any event
prior to the Closing which would cause any representation, warranty or covenant of such party contained in this Agreement to be
false or incorrect.


 


26.           Severability.
If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality
or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such
term or provision in any other jurisdiction.


 






    22


     


    

 


27.           Independent
Nature of Investors’ Obligations and Rights. The obligations of each Investor under this Agreement are several and not
joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance or non-performance
of the obligations of any other Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant
hereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity,
or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or
the transactions contemplated hereby. Each Investor shall be entitled to independently protect and enforce its rights, including
the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party
in any proceeding for such purpose. Each Investor has been represented by its own separate legal counsel in its review and negotiation
of this Agreement (including the exhibits and schedules hereto). Except as expressly contemplated by this Agreement, the Company
has elected to provide all Investors with the same terms and Agreement for the convenience of the Company and not because it was
required or requested to do so by any of the Investors.


 


28.           Interpretation.
For purposes of this Agreement, (i) the words “include,” “includes” and “including” shall
be deemed to be followed by the words “without limitation,” (ii) the word “or” is not exclusive, (iii)
reference to any gender includes the other gender and the neutral gender (and vice versa) and (iv) the words “herein”,
“hereof”, “hereby”, “hereto” and “hereunder” refer to this Agreement as a whole.
Unless the context otherwise requires, references herein: (a) to Articles, Sections, Exhibits and Schedules mean the Articles
and Sections of, and the Exhibits and Schedules attached to, this Agreement; (b) to an agreement, instrument or other document
means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted
by the provisions thereof and by this Agreement; and (c) to a statute means such statute as amended from time to time and includes
any successor legislation thereto and any regulations promulgated thereunder. The Schedules and Exhibits referred to herein shall
be construed with and as an integral part of this Agreement to the same extent as if they were set forth verbatim herein. This
Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party
drafting an instrument or causing any instrument to be drafted.


 


[Signature pages follow]


 






    23


     


    

 


IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.


 


	 	MARINUS PHARMACEUTICALS, INC.
	 	 
	 	 
	 	By: 	/s/ Edward Smith
	 	Name:	Edward Smith
	 	Title:	 CFO





 





[Signature Page to Securities Purchase
Agreement]




 






    


     


    

 


	 	LION POINT MASTER, LP
	 	 
	 	By:	LION POINT CAPITAL, LP, as Manager
	 	 
	 	 
	 	By:	/s/ Irshad
Karim
	 	Name:	Irshad Karim
	 	Title:	General Counsel


 





[Signature Page to Securities Purchase
Agreement]




 






    


     


    

 


	 	Avoro Life Sciences Fund LLC
	 	 	 

	 	 	 
	 	By:	/s/ Scott Epstein
	 	Name:	Scott Epstein
	 	Title:	CFO & CCO


 





[Signature Page to Securities Purchase
Agreement]




 






    


     


    

 


	 	BOXER CAPITAL, LLC
	 	 	 
	 	 	 
	 	By:	/s/ Aaron Davis
	 	Name:	Aaron Davis
	 	Title:	Chief Executive Officer


 





[Signature Page to Securities Purchase
Agreement]




 






    


     


    

 


	 	By:	/s/
    Leif Edlund
	 	Name:	For and on behalf of Venture Holding S.a.r.l.,
    Leif Edlund
	 	Title:	Director A


 





[Signature Page to Securities Purchase
Agreement]




 






    


     


    







 


SCHEDULE I


 


SCHEDULE OF INVESTORS


 





	Investor’s Name and Address	 	Number of

Securities	 	 	Purchase Price	 
	Lion Point Master, LP 

Lion Point Capital 

250 West 55th Street, 33rd Floor 

New York, NY 10019	 	 	14,125	 	 	$	14,125,000	 
	Avoro Life Sciences Fund LLC 

Avoro Capital Advisors 

110 Greene Street, Suite 800 

New York, NY 10012	 	 	5,250	 	 	$	5,250,000	 
	Boxer Capital, LLC

11682 El Camino Real, Suite 320 

San Diego, CA 92130 	 	 	6,000	 	 	$	6,000,000	 
	Venture Holding

UBS Europe SE, Luxembourg Branch 

Attn: Eva Serlachius 

33A, Av. J.F. Kennecy, P.O. Box 2 

L-2010 Luxembourg 

Luxembourg 	 	 	4,625	 	 	$	4,625,000	 
	Total	 	 	30,000	 	 	$	30,000,000	 







 






    


     


    




 


ANNEX I


 


RULE 506 DISCLOSURE


 


The following is a description of matters
that are required to be disclosed pursuant to an undertaking to which Oppenheimer & Co. Inc. (“Oppenheimer”) is
subject or pursuant to Rule 506(e) adopted under the Securities Act of 1933, as amended, with respect to Oppenheimer and its financial
advisors who may be paid for soliciting sales of securities pursuant to Rule 506.


 


1.             On
February 26, 2010 Oppenheimer entered into a Consent Order with the Massachusetts Securities Division (the “Division”).
The Order concerned alleged violations of the Massachusetts Uniform Securities Act with respect to Oppenheimer’s sale of
auction rate securities. The order found that Oppenheimer violated Section 204(a)(2)(G) of Chapter 110A of Massachusetts General
Laws. Oppenheimer was required to buy back illiquid auction rate securities from investors and pay hearing costs in an amount totaling
$250,000.


 


2.             On
July 9, 2007 Oppenheimer entered into a Consent Order with the Massachusetts Securities Division (the “Division”).
The Order alleged that Oppenheimer failed to supervise a registered representative who engaged in unlawful activities. The Division
alleged that Oppenheimer made false and misleading filings to the Division during the course of its investigation of the matters
addressed in the Order and accordingly violated Massachusetts General Laws, Chapter 110A, Section 404. Oppenheimer was required
to pay a fine of $1,000,000, make restitution to the investor, cease and desist from further violations and retain an independent
consultant.


 


3.             On
January 27, 2015, Oppenheimer entered into an order with the Securities and Exchange Commission (“SEC”) pursuant to
which Oppenheimer was censured and agreed to (i) pay $10 million, comprised of $4,168,400 in disgorgement, $753,471 in prejudgment
interest and $5,078,129 in civil penalties; (ii) cease and desist from committing or causing any violations of Sections 15(a) and
17(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rules 17a-3 and 17a-8 adopted thereunder and
of Section 5 of the Securities Act of 1933 (the “Securities Act”); and (iii) retain an independent consultant over
a five-year period to conduct a review of Oppenheimer’s policies and procedures as they relate to compliance with Section
5 of the Securities Act, the Bank Secrecy Act, the Patriot Act, Oppenheimer’s AML program and the proper recognition of liabilities
and expenses associated with foreign entities trading on behalf of customers and U.S. customers trading through foreign financial
institutions. This settlement was based on Oppenheimer’s conduct relating to two separate customer accounts. The first account
involved aiding and abetting a customer’s violation of the broker-dealer registration requirements under the Exchange Act,
failure to file Suspicious Activity Reports to report potential misconduct by this customer and failure to properly report, withhold
and recognize backup withholding taxes. The second account involved failure to respond to red flags and conduct an inquiry into
whether a customer’s unregistered sales of penny stocks were exempt from Securities Act registration requirements and failure
to reasonably supervise with a view toward detecting and preventing violations of the registration provisions. Oppenheimer also
agreed to pay an additional $10 million in civil penalties to settle a parallel action by the Treasury Department’s Financial
Crimes Enforcement Network.


 






    


     


    







 


EXHIBIT A


 


FORM OF CERTIFICATE OF DESIGNATIONS